cyrilzakka/clinical-trials huggingface dataset:
Impact of the Wingate Test on Post-activation Potentiation

The goal of this trial is to see if using a maximal effort, short cycling test is better at activating muscles to improve vertical jump height compared to a maximal effort back squat. The study looks to answer three questions:

1. will the Wingate bike test create a different change in counter movement jump height compared to a back squat?
2. What is the best recovery period after each test where the counter movement jump is the highest?
3. What person-specific factors predict success of the Wingate bike test as a activation activity for the counter movement jump? Participants will visit the lab 3 times, once to give informed consent and measure their 1 repetition max (RM) back squat, and twice to perform each intervention and measure vertical jump height.

Participants will be asked to come to the lab for three visits. On the first visit, they will perform informed consent, have anthropometrics taken, and will provide data to assess weightlifting history and factors that may influence the impact of each intervention. They will perform a 1 repetition max (RM) test for the back squat in order to properly dose the back squat potentiation activity. Visits 2 and 3 will be randomized; one will use the back squat (control) and the other will use the Wingate bike test (experimental) to potentiate vertical jump height as measured by the counter movement jump (CMJ). In each session, a warm up will be performed and the baseline CMJ will be performed. The intervention will be performed, either the 30 second Wingate protocol which is a maximal effort cycling test, or the back squat at a high percent of the 1 RM. The CMJ will be reassessed at 3, 6, and 9 minutes after completed each intervention.

Eligibility Criteria:
Inclusion Criteria:

* healthy adult
* successful completion of the physical activity readiness questionnaire plus
* at least 1 year of back squat weight training experience

Exclusion Criteria:

* inability to back squat at least 1.4 times body weight
* females with known pregnancy
DIETary Intake, Death and Hospitalization in Adult With End-stage Kidney Disease Treated With HemoDialysis (DIET-HD) Study

The DIETary intake, death and hospitalisation in adults with end-stage kidney disease treated with HaemoDialysis (DIET-HD) study is a multinational prospective cohort study designed to evaluate the association between nutrition and dietary patterns and health outcomes in prevalent adult haemodialysis patients in Europe and South America.


Eligibility Criteria:
Inclusion Criteria:

* End-stage kidney disease
* Long-term haemodialysis for at least the previous 90 days
* 18 years or older
* Treating team agrees to the patient's involvement in the study
* Participant willing to provide written and informed consent.-

Exclusion Criteria:

* significant neurocognitive disability or medical comorbidity that would preclude them from understanding the dietary questionnaire even if assisted
* a life expectancy less than 6 months according to their treating physician
* planned kidney transplantation within 6 months of baseline
Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

The objective of this study to evaluate the efficacy FG-4592 for the treatment of anemia in Chinese participants with lower risk MDS.

This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each part, there is an up to 4 weeks screening period followed by a treatment period of 26 weeks and a 4 week follow-up period.

Eligibility Criteria:
Key Inclusion Criteria:

* Diagnosis of primary MDS classified as very low, low or intermediate risk with \<5% blasts (documented within 12 weeks prior to Day 1)
* Screening Hb \<10 g/dL and ≥6g/dL
* Transfusion independent defined as no red blood cell transfusions within 12 weeks of Day 1
* Erythropoiesis-stimulating agent (ESA)-naïve (not within 30 days of Day 1)
* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

Key Exclusion Criteria:

* Diagnosis of secondary MDS
* Significant myelofibrosis (\>2+fibrosis)
* Prior therapy with azacitidine, decitabine, antithymocyte globulin, cyclosporine, thalidomide, or lenalidomide within 12 weeks prior to Day 1
* Baseline erythropoietin level of \>400 units (U)/liter (L)
* Clinically significant anemia due to non-MDS etiologies

Note: Other inclusion and exclusion criteria may apply.
Acetylsalicylic Acid and Type 2 Diabetes Mellitus

OBJETIVE To assess the effect of acetylsalicylic acid on antioxidant enzymatic system in patients with type 2 diabetes

A randomized, double blind placebo controlled clinical trial was carried out in 21 adult patients with type 2 diabetes. Acetylsalicylic acid 300mg/d was administered orally for 3 months to study group (n=11) and placebo to the control group (n=10).

Eligibility Criteria:
Inclusion Criteria:

* Type 2 Diabetes
* BMI 25.0 - 35.0 kg/m2
* HbA1c between 6.5 - 9%.
* Written informed consent
* Same residential area and socioeconomic status.

Exclusion Criteria:

* Sedentary or heavy physical activity.
* Nonsmokers.
* Body weight was stable for al last 3 months before the study.
* Personal history of hepatic, renal, gastric or coronary artery disease.
* Hypersensibility to acetylsalicylic acid.
Oxaliplatin in Gastric Cancer

To determine the objective response to oxaliplatin/5FU/leucovorin combination chemotherapy in patients with advanced unresectable or metastatic gastric cancer.


Eligibility Criteria:
Inclusion Criteria:

* ECOG performance status of 0-2.
* Histologically proven gastric or gastro-esophageal junction adenocarcinoma.
* At least unidimensional measurable disease. If a unique metastasis constitutes the only disease sign, it requires histological confirmation.
* First line locally unresectable or metastatic gastric cancer.
* Relapsing gastric cancer after local and/or systemic treatment with a post-surgical period of at least 4 weeks, a post-adjuvant or neoadjuvant chemoradiotherapy period of at least 6 months.
* Serum bilirubin \< 2 mg/dl
* Serum creatinine \< or = 2 mg/dl
* Hemoglobin \> or = 10 g/dl
* Absolute neutrophil count \> or = 2000/dl
* Platelet count \>or = 100, 000/dl
* AST/ALT \< or = 2.5 time-fold the institutional normal upper limit
* Alkaline phosphatase \< or = 5 time-fold the institutional normal upper limit
* Imagenological evaluation of the patient at least 2 weeks prior to the drug infusion
* Laboratory tests at least 1 week prior to the first infusion
* Patient available for follow up and able to answer to the quality of life questionnaire

Exclusion Criteria:

* Symptomatic sensorial peripheral neuropathy
* Uncontrolled concomitant disease
* Another malignant neoplastic disease diagnosed within the previous 5 years to the diagnosis of advanced or metastatic gastric cancer, with the exception of 'in situ' cervix carcinoma or non-melanoma skin cancer
* Concomitant antitumoral treatment
* Cerebral metastases
* Unstable heart disease, even though in treatment
* Myocardial infarction within the last 6 months
* Radiotherapy within the last 6 weeks, surgery within the last 4 weeks, or chemotherapy within the last 6 months.
* Pregnancy or nursing ( or women in reproductive life without adequate contraception)
* Significant neurological or psychiatric disorders.
Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy.

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy. The propose of this work was to evaluate the production of IFN- γ in cell supernatants of peripheral blood mononuclear cells (PBMC) culture, TNF-α, IL-10 and TGF-b in cell supernatants of monocytes (MO) culture and biochemical (total proteins, albumin, globulin, α-1-acid glycoprotein and C-reactive protein) and hematological (VHS) serum parameters before and after 3 and 6 months of therapy

Eligibility Criteria:
Inclusion Criteria:

* diagnosis of Mycobacterium tuberculosis infection

Exclusion Criteria:

* all other granulomatous or neoplastic diseases
Malaria Active Epidemiology and Treatment Study

An observational cohort and malaria treatment study in Cambodia.

This is an active observational Cohort Study of malaria epidemiology with a nested two arm, randomized, open label Treatment Study comparing the efficacy, safety, tolerability and pharmacokinetics of a two versus three day course of Dihydroartemisinin-Piperaquine (DP) for those developing uncomplicated malaria. At the conclusion of the Cohort Study, a subset of volunteers with documented exposure to Plasmodium vivax during the study will be treated with primaquine as presumptive anti-relapse therapy directed against the exoerythrocytic malaria stages of P. vivax, and followed passively for an additional 6 months.

Eligibility Criteria:
Inclusion Criteria:

1. Otherwise healthy volunteer, 18-65 years of age, eligible for care at an RCAF facility, and at risk for contracting malaria
2. Able to provide informed consent
3. Likely to reside in endemic area for the duration of the study
4. Available for follow-up for anticipated study duration, and agrees to participate for the duration of the study
5. Authorized by local commander to participate in the study if on active duty

Exclusion Criteria:

1. History of allergic reaction or contraindication to DHA or piperaquine
2. Significant acute comorbidity requiring urgent medical intervention
3. Pregnant or lactating female, or a female of childbearing age who does not agree to use a highly effective method of birth control during the study
4. Clinically significant abnormal EKG, including a QTc interval \> 500 ms.
5. Judged by the investigator to be otherwise unsuitable for study participation
The Role of Antibiotics After Surgical Treatment of Simple Hand Infections: A Prospective Study

Three patient groups with simple hand infections are tested regarding the necessity of antibiotics after surgical treatment.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients with simple hand infections

Exclusion Criteria:

* Infection of the bone, tendon or joint
* Major diseases like diabetes or immunodeficiency
* Systemic manifestations like fever or lymphangitis
* Bite infections
HUD: PIP Joint Implant

This surgery involves the use of a finger joint replacement device for treatment of patients with certain kinds of arthritis (osteo - arthritis or post traumatic arthritis) and who expect to place their hands in heavy loading situations, or patients needing revision of a failed implant placed in the PIP joint. A joint replacement surgery is an operation where the arthritic joint is removed and a metal and plastic joint is inserted to replace the natural joint. The surgery is expected to last about 2 hours. The procedure is done in the operating room and requires general anesthesia or an axillary block. (General anesthesia affects the entire body and is accompanied by a loss of consciousness. An axillary block results in anesthesia of the hand and forearm only. A tourniquet is applied to the arm to prevent bleeding during the surgery.)


Eligibility Criteria:
Inclusion Criteria:

* Patients with disability of the their finger from arthrosis

Exclusion Criteria:

-
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic

This study will determine the safety profile and maximum tolerated dose (MTD) of orally administered gefitinib on a weekly and twice weekly schedule.


Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed solid tumor refractory to conventional treatment or whom no standard of treatment exists
* Life expectancy of \> 12 weeks
* World Health Organization (WHO) performance status of \< 2

Exclusion Criteria:

* Known severe hypersensitivity to gefitinib or any of the excipients of this product
* Less than 4 weeks since completion of prior chemotherapy or radiation therapy (except nitrosoureas or mitomycin-C which must have a wash out period of 6 weeks)
* Incomplete healing from previous oncologic or other major surgery
Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Cadonilimab（AK104）is a humanized IgG1 bispecific antibody that targets PD-1 and CTLA-4.

This is a single-arm, multicenter, open-label, phase II study, the purpose of this study is to evaluate the efficacy and safety of Cadonilimab plus radiotherapy in participants with locally advanced cervical cancer who do not tolerate chemotherapy.


Eligibility Criteria:
Inclusion Criteria:

1. Able to understand and voluntarily sign written informed consent.
2. Women aged ≥18 years at the time of study entry.
3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-2.
4. Life expectancy ≥12 weeks.
5. Intolerance to chemotherapy regimens.
6. Histologically confirmed cervical cancer.

   1. Histologically-confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix;
   2. Not receiving systemic anti-tumour therapy (including but not limited to radiotherapy, targeted therapy and immunotherapy, etc; concurrent chemotherapy is not included. Note: Removal or biopsy of pelvic lymph nodes or para-aortic lymph nodes for the purpose of clinical staging is allowed).
   3. Locally advanced cervical cancer（LACC）: The International Federation of Gynecology and Obstetrics (FIGO) 2018 Stage IB3/IIA2, IIB-IVA.
7. At least one measurable tumor lesion according to RECIST v1.1 criteria.
8. Available archived tumor tissue samples or recent biopsies.
9. Adequate organ function.
10. For fertile women with negative serum pregnancy and effective contraception within 7 days before administration (until 120 days after the last administration of the study drug and at least 180 days after radiotherapy)

Exclusion Criteria:

1. Other histological types of cervical cancer (eg, neuroendocrine carcinoma, small cell carcinoma, sarcoma, etc).
2. Evidence of distant metastases.
3. Have received total hysterectomy.
4. Subject with other active malignancies within 2 years prior enter the study.
5. Subject who cannot receive brachytherapy.
6. Active or prior documented autoimmune disease that may relapse.
7. History of interstitial lung disease or noninfectious pneumonitis.
8. Subject with the clinically significant cardio-cerebrovascular disease.
9. History of severe hypersensitivity reactions to other mAbs.
10. Prior allogeneic stem cell transplantation or organ transplantation.
11. Subjects who require systemic treatment with glucocorticoid (\>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior enter the study.
12. Receipt of live attenuated vaccines within 30 days prior to the first dose of the study drug.
13. Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).
14. Any condition that, in the opinion of the Investigator, would interfere with the evaluation of the study drug or interpretation of subject safety or study results.
Prediction of Future Weight Change With Dopamine Transporter

This is the re-analyzing study of observational study by Parkinson's Progression Markers Initiative


Eligibility Criteria:
Inclusion Criteria:

* males or females with their age of 30 years or older at screening

Exclusion Criteria:

* subjects with a neurological disorder, a first degree relative with idiopathic PD, Montreal Cognitive Assessment score of 26 or less, medications that might interfere with DAT SPECT scans, anticoagulants that might preclude safe completion of the lumbar puncture, or investigational drugs, and a condition that precludes the safe performance of routine lumbar puncture
Kinesiophobia in Stroke Patients and Affecting Factors

It was aimed to determine the presence of kinesiophobia that will affect the treatment in stroke patients and to investigate the relationship between these factors and kinesiophobia by examining factors such as postural control, depression, pain, and affected side that may cause kinesiophobia.

Objective: This study was planned to investigate the relationship between depression, postural control, pain, affected side and kinesiophobia in stroke patients. Material and Method: Thirty patients aged between 25-70 years who had a stroke at the earliest 6 months and who Functional Ambulation Scale were level 2 and above according to the were included in the study. Patients were selected by random sampling method from the relevant population. Demographic data were obtained from all subjects who met the inclusion criteria. Patients were evaluated Kinesiophobia scores (Tampa Kinesiophobia Scale (TKÖ) and VAS-Kinesiophobia Assessment), depression severity (Beck Depression Inventory), postural control loss (PASS) and pain severity (VAS).

Eligibility Criteria:
Inclusion Criteria:

* individuals who were diagnosed with hemiplegia or hemiparesis after SVO,
* at least 6 months after SVO,
* who were Level 2 and above according to the Functional Ambulation Classification,
* who wanted to participate in the study voluntarily

Exclusion Criteria:

* Anyone with a major neurological or rheumatological pathology (polyneuropathy, parkinson's, multiple sclerosis, rheumatoid arthritis, etc.)
* Affecting the musculoskeletal system other than stroke
* Who does not allow mental evaluation, cannot fill in the scales,
* is illiterate, has aphasia, has a history of falling,
* have any cardiac problems,
* amputation in the lower extremities,
* those with active malignancy and related chemo/radiotherapy,
* the presence of accompanying lower motor neuron or peripheral nerve lesion,
* any musculoskeletal problem and related pain (lumbar disc herniation, meniscus, etc.),
* ındividuals with shoulder subluxation, shoulder-hand syndrome
* those who refused to participate in the study
Fungemia in Hematologic Malignancies

The purpose of this study is to determine the risk factors for fungemia in a population of patients diagnosed with hematologic malignancies and eligible for chemotherapy.

The coordinating center provides all participating centers with an epidemiologic form, in order to collect data in a comparable way. The requested informations include type of malignancy and its treatment, environmental expositions, laboratory work up, antifungal prophylaxis, clinical signs of infection, microbiological findings, antifungal therapy and outcome of infection at 30 days.

The planned sample size is about 300 patients to be recruited in 35 participating center over 5 years, in a retrospective-prospective fashion. Data check will be performed at the coordinating center. Missing data will be managed to minimize incomplete reports.

Statistical analysis will be performed by an independent reviewer, in order to assess risk factors predictive of fungal infection and outcome.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with hematologic malignancies and eligible to chemotherapy

Exclusion Criteria:

* Patients not eligible to chemotherapy
Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

This is a prospective randomized open-label cross-over study. Poor responder patients will undergo two ovarian stimulation cycles. One with recombinant follicle stimulation hormone (FSH), and an other stimulation with recombinant FSH and recombinant luteinizing hormone (LH). In both groups, a freeze-all strategy will be applied and an endometrial biopsy will be taken 7 days after final oocyte maturation trigger. Endometrial gene expression analysis will be performed on both biopsies. After completion of both treatment cycles, a frozen embryo transfer of a single embryo will be performed.

This is a prospective randomized open-label cross-over study, in which patients will be randomized to either start in the control group or in the study group. Participants will undergo both treatments with an interval of minimum 1 and maximum 6 months. In both treatment arms, ovarian stimulation will be started at day 2/3 of the menstrual cycle. In the control group, 225 IU of recombinant FSH will be administered in a fixed antagonist protocol. In the study group, 225 IU of recombinant FSH plus 112,5 IU of recombinant LH will be administered. Cycle monitoring will be performed through serum estradiol (E2), progesterone (P), and luteinizing hormone (LH) assessments, combined with serial ultrasound examinations. Both groups will undergo dual triggering with gonadotropin releasing hormone agonist (GnRHa) 0,2ml and human chorionic gonadotrophin (hCG) 6500IU if one or more follicles of ≥ 17 mm are observed. The oocyte retrieval (OR) will be performed between 34 and 36 hours after final oocyte maturation trigger. At each OR, follicles will be individually meas-ured, aspirated and searched for the presence of cumulus oocyte complexes (COC). Metaphase II (MII) oocytes will then be injected to standard intra-cytoplasmatic sperm injection (ICSI) procedures. In both groups, a freeze-all strategy will be applied. An endometrial biopsy (Pipelle de Cornier ®) will be taken 7 days after final oocyte maturation trigger. After completion of both treatment cycles, a frozen embryo transfer of a single embryo will be performed.

Eligibility Criteria:
Inclusion Criteria:

* Age 35-40 years
* Undergoing IVF/ICSI
* BMI ≥ 19 and ≤ 30
* AMH \<1.2 ng/mL
* Previous conventional ovarian stimulation (OS) with \< 4 metaphase II (MII) oocytes
* Regular menstrual cycle (26-35 days)
* Non-smokers
* Acceptance to do 2 consecutive ovarian stimulation cycles (between 1-6 months)
* Signed informed consent

Exclusion Criteria:

* Endometriosis \> rAFS grade II
* Testicular sperm extraction
* Recurrent miscarriage (\>2 previous miscarriages)
* Ovarian stimulation for pre-implantation genetic testing (PGT-A/M)
* Medical/social oocyte vitrification
* In vitro maturation (IVM)
* Untreated auto-immune, endocrine or metabolic disorders
* Asherman's syndrome